VS-6766+Abema+Fulv in Met HR+/HER- BC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions: DRUG: VS-6766|DRUG: Abemaciclib|DRUG: Fulvestrant
Sponsor: Adrienne G. Waks
Collaborators: Verastem, Inc.|Eli Lilly and Company